Results

1–10 of 27 results for anti-VEGF injections

National vs International Outcomes and Practice Patterns of Intravitreal Anti-VEGF Injections for Retinopathy of Prematurity
Nimesh A. Patel, MD
Annual Meeting Talks
2022
The Impact of the COVID-19 Pandemic on Aflibercept and Ranibizumab Anti-VEGF Injections
Kapil Mishra, MD
On Demand Cases, Courses, and Papers
2021
PRN Cycles of Three Monthly Anti-VEGF Injections in Diabetic Macular Edema: 12- and 24-Month Results
Ahmad Rehmani, DO
On Demand Cases, Courses, and Papers
2021
Loss to Follow-up in Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2021
A 10-Year Follow-up on Outcomes of Intravitreal Anti-VEGF Injections for Choroidal Neovascularization Secondary to Ocular Histoplasmosis
Carl Noble, DO, MBA
Annual Meeting Talks
2021
The Influence of Universal Face Mask Use on Endophthalmitis Risk After Intravitreal Anti-VEGF Injections During the COVID-19 Pandemic
Sunir J. Garg, MD, FACS, FASRS
Annual Meeting Talks
2021
Comparing Rates of Vitrectomy in Proliferative Diabetic Retinopathy Patients Treated With Anti-VEGF or Panretinal Photocoagulation Monotherapy
Nadim M Rayess, MD
Annual Meeting Talks
2021
Loss to Follow-up in Patients With Neovascular Age-Related Macular Degeneration Treated With Anti-VEGF Therapy in the United States
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2020
Ten-Year Follow-Up of Patients With Exudative Age-Related Macular Degeneration Treated With Intravitreal Anti-VEGF Injections
Sophie Jane Bakri, MD
Annual Meeting Talks
2020
Intravitreal Anti-VEGF Injections for Exudative Retinal Arterial Macroaneurysms: Results of an International Multicenter Study
J. Fernando Arevalo, MD, PhD, FACS, FASRS
Annual Meeting Talks
2020